Plasminogen activator-plasmin system potentiates the proliferation of hepatocytes in primary culture

Background/AIMS: Liver regeneration after partial hepatectomy is thought to be regulated by various molecules including the components of the plasminogen activator (PA)-plasmin system. We have examined the role of fibrinolytic factors, i.e., tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), and their substrate, plasminogen, in the proliferation of hepatocytes in primary culture. METHODS: Hepatocyte and nonparenchymal liver cells were isolated from Wistar strain rat by a method perfusing the liver with collagenase. DNA synthesis was assessed by measuring the incorporation of [3H]-thymidine into cellular DNA fraction. tPA, uPA and type-1 plasminogen activator inhibitor (PAI-1) gene expressions were measured by Northern blotting. PA activity was measured by fibrin/agarose plate method. RESULTS: Cellular density-dependent DNA synthesis was observed in the primary cultured hepatocytes; DNA synthesis was lower at high cell density (1.0 x 10(5) cells/cm(2)) than that at low cell density (0.2 x 10(5) cells/cm(2)). DNA synthesis in the hepatocytes cultured at a low cell density was increased by co-culture with nonparenchymal liver cells. Under these growth-stimulated culture conditions, tPA and uPA mRNAs were induced and up-regulated. On the contrary, the PAI-1 mRNA level was decreased under these conditions, and total PA activity was augmented accordingly. The synthetic plasmin inhibitor tranexamic acid, a competitive inhibitor for the plasmin molecule, and PASI-535, a plasmin active center-directed inhibitor, both suppressed hepatocyte proliferation in a dose-dependent fashion. Anti-plasmin antibody also suppressed hepatocyte proliferation. CONCLUSIONS: The up-regulation of PA activity for ensuring plasmin activity should be an important mechanism in the proliferation of hepatocytes.     

Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes.

Two plasminogen activators (PAs): tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), as well as the type-1 plasminogen activator inhibitor (PAI-1) are synthesized and secreted by rat astrocytes. Preliminary studies suggest that PA activity plays a role in astrocyte development and differentiation. We have examined the regulation of the PA system by the cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) in purified rat astrocyte cultures. PKA activity was increased by exposing cultured astrocytes to forskolin or dibutyryl cyclic AMP, whereas PKC activity was stimulated with phorbol-12-myristate 13-acetate (PMA). Activation of both second-messenger pathways produced a time- and dose-dependent increase in the total PA activity. However, based on SDS-PAGE/zymography we found that forskolin increased t-PA activity and reduced u-PA activity, whereas PMA treatment caused a significant increase in u-PA activity without altering t-PA activity. Reverse zymography analysis revealed that astrocyte PAI-1 activity is decreased by forskolin and increased by PMA. Together, these results demonstrate that the components of the PA system in rat astrocytes are independently and reciprocally regulated by PKA and PKC. Our findings raise the possibility that the plasminogen activator system could be involved in some of the actions of growth factors and/or neuromodulators that modulate PKC or PKA in astrocytes.     

Concurrent expression of procoagulant and plasminogen activator activities by rabbit alveolar macrophages in vitro: opposite modulating effects of prostaglandin E2

We examined the effects of arachidonic acid metabolites on the simultaneous expression of procoagulant (PC) and plasminogen activator (PA) activities by rabbit alveolar macrophages. Incubation with lymphocyte-conditioned medium (LCM) caused a significant increase in cell-associated PC activity. Co-treatment with indomethacin (1 microM) reduced this augmentation in PC activity by 33% (p less than 0.05). In contrast, indomethacin caused a 42% increase in PA activity released into incubation medium (p less than .05). Both effects of indomethacin were reversed by the addition of PGE2 in concentrations as low as 1 nM. Addition of 100 nM PGE2 to these cells caused an increase in PC activity 2.7-fold greater than that achieved by LCM alone, while PGE2 suppressed released PA activity by 62%. PGE2 and indomethacin had similar but less pronounced effects on phorbol myristate acetate-treated cells. These effects of PGE2 could be duplicated by PGE1, but not by any other arachidonic acid metabolite (PGF2 alpha, PGI2, PGD2, ddPGF2 alpha, LTB4, or LTC4). While PGE2 increases intracellular levels of cAMP, the observed effects on PC and PA activities could not be reproduced fully by treatment with dibutyryl cAMP. We conclude that PGE2 amplifies the augmentation of PC activity by stimulated alveolar macrophages while concurrently inhibiting expression of plasminogen activator. This suggests that PGE2 may be a significant mediator in regulating the highly interactive processes of inflammation and coagulation/fibrinolysis.     

Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60

The effects of maturation inducing agents on the production of plasminogen activator (PA) and plasminogen activator inhibitor (PAI) by the human promyelocytic leukemia cell line HL-60 were examined. PA activity, which was calibrated with a urokinase standard, was 3-6 mU/10(6) cells when measured in supernatants from control cells. This activity increased at least two-fold after dimethylformamide (DMF) or retinoic acid (RA) was added to cell cultures, and as much as ten to thirty-fold when cells were exposed to 12-O-tetradecanoylphorbol-13-acetate (PMA), an agent that induces monocytoid differentiation in HL-60 cells. The PA activity produced by control and induced cells had the same molecular weight as urokinase (UK), and was completely inhibited by antibodies to UK. Cells that were induced with PMA but not with RA or DMF also produced an inhibitor to UK that was identified as PAI-2, the plasminogen activator inhibitor that is produced by monocytes. Because of its dual capacity to produce both UK and PAI, the HL-60 cell line represents a useful model for studies of the fibrinolytic mediators that are generated and released by leukemia cells.     

Relationship between age and plasma t-PA, PA-inhibitor, and PA activity

A positive correlation between age and the occurrence of thrombosis has been suggested. We studied the relationship between age and fibrinolytic activities; namely levels of tissue plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PA inhibitor) activity, and plasminogen activator activity (PA activity). A dramatic increase in both t-PA antigen and PA inhibitor was shown in persons with increasing age. PA activity decreased with age. Therefore it is suggested that the tendency of decreased PA activity with increasing age may be related to the high incidence of thrombosis in older persons.     

An assay system for the modulators of plasminogen activation on the cell surface

Plasminogen activation on the cell surface is regulated by a variety of modulators which balance surface-bound plasminogen activators (PAs) and plasminogen activator inhibitors (PAIs). In this study, we developed as assay system to assess modulation of cell-associated plasminogen activation. Plasmin generation by endogenous plasminogen activators was measured with a combination of exogenously added plasminogen and a chromogenic substrate, S-2251, in the presence of living cells. A cell surface PA activity was quantitated by adopting a rate of plasmin generation. We used HT-1080, a human fibrosarcoma cell line, as representative of cells which have both PAs and PAIs on their cell surface. A basal level of cell surface PA activity was specifically reduced by anti-urokinase-type PA IgG and enhanced by anti-PAI-1 IgG, suggesting that the basal level is determined by a balance between uPA and PAI-1 on the cell surface. We examined effects of dexamethasone and thrombin on cell surface PA activity in the assay system. Dexamethasone appeared to suppress the cell surface PA activity by enhancing de novo synthesis of PAI-1, whereas thrombin suppressed it by inactivating single-chain urokinase-type plasminogen activators. These results indicate that our assay system can be adapted for the screening of various types of PA modulators.     

Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells

Human foreskin microvascular endothelial cells synthesize and release tissue-type plasminogen activator (t-PA) in similar amounts as do endothelial cells from umbilical cord artery and vein. Human thrombin increases the production of t-PA by these cells, which could be visualized from 8 h after addition of 0.1-5 units/ml thrombin by fibrin autography after SDS polyacrylamide gel electrophoresis of the endothelial cell conditioned media. Thrombin also increased the secretion of t-PA antigen. Together with t-PA, human microvascular cells release urokinase-type plasminogen activator (u-PA) antigen and endothelial cell-type PA inhibitor, PA inhibitor-1, which were both demonstrated by specific immunoprecipitation from radiolabeled endothelial cell conditioned medium. Thrombin increases the release of u-PA antigen, but no u-PA activity could be demonstrated. Thrombin induced a two-fold stimulation of the synthesis and secretion of PA inhibitor-1 antigen. At 0.1 unit/ml thrombin also an increase in PA inhibitor activity was found. At high concentrations of thrombin a decrease of PA inhibitor activity was found, due to the conversion of the active 46 kD PA inhibitor-1 into a 42 kD product without PA inhibitor activity. Our data indicate that interaction of thrombin with microvascular endothelial cells will shift the balance between t-PA, u-PA and PA inhibitor-1, and thus affects the regulation of fibrinolysis.     

Comparison between the plasminogen activator activity in walls of superficial,muscle and deep veins

Determinations were made of the plasminogen activator activity (PA) of biopsy specimens of the great saphenous vein and at the same level of the femoral or the popliteal vein in 35 patients undergoing amputation of the leg because of arterial insufficiency and in one because of deep venous insufficiency. The PA was measured with a modification of Todd's fibrin slide technique. In 21 patients the PA was also determined in biopsy specimens of a muscle vein at the same level of the leg. The PA of the walls of superficial veins proved significantly lower than that of the walls of deep major veins. No difference in activity was demonstrable between muscle veins and deep major veins. A significant correlation was found between the PA of superficial and deep veins.     

Tissue plasminogen activator binding to mouse cerebellar granule neurons

Cultures of dissociated neonatal mouse cerebellar cells secrete primarily tissue plasminogen activator (tPA) and to a lesser extent urokinase plasminogen activator (uPA) into the culture medium. Fibrin overlays have localized plasminogen activator to granule neurons in these cultures; furthermore, this granule cell plasminogen activator activity is blocked by an antibody to tPA. Developmental studies indicate that maximal levels of soluble plasminogen activator in the culture medium preceed the peak of fibrinolytic activity by these cultures, suggesting that secreted PA may bind back to the surface of these granule neurons. Here we show that granule cell-associated tPA can be displaced by a brief pH shock. However, incubation of these fibrinolytically inactive cultures with exogenously added mouse tPA leads to a specific binding of active tPA to granule neurons as visualized by subsequent fibrin overlay. In similar studies mouse uPA, human uPa, and human tPA fail to show fibrinolytic activity associated with the cerebellar culture, whereas mouse tPA fails to bind to cerebellar glial cell cultures. These findings suggest that granule neurons possess binding sites for tPA on their surface, where this protease can retain its functional activity and may play an important role in cell migration or other cell activities.     

Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis

Fibrinolytic activity in the form of plasminogen activator (PA) was assessed using a histochemical fibrin slide technique in spinal cords of normal Lewis rats and rats with the cell-transferred form of experimental allergic encephalomyelitis (EAE). PA was localized exclusively to blood vessels. Vessels in the leptomeninges had maximum activity. A precipitous decrease in PA activity occurred in recipient rats which coincided with onset of clinical neurologic signs. A subsequent return in activity occurred in association with clinical remission of disease but remained well below the activity level of normal rats for as long as the recipient animals were followed. Vessels containing perivascular cellular infiltrates of EAE had little or no detectable PA activity. Furthermore, PA could not be demonstrated to be associated with infiltrating inflammatory cells, including macrophages. These findings provide further support for involvement of the coagulation and fibrinolytic systems in the early clinical manifestations of EAE in Lewis rats.     

脑梗死患者血纤溶系统活性指标的改变和预后的关系

目的 研究脑梗死患者血浆组织型纤溶酶原激活物（ｔ－ＰＡ）及其抑制物（ＰＡＩ－１）水平的改变和预后的关系。方法 对１１２例脑梗死患者进行了血浆ｔ－ＰＡ、ＰＡＩ－１、血糖、血脂的检测及神经功能缺损程度的评分。分为脑梗死组,再梗死组和正常对照组进行比较;并根据神经功能缺损程度的评分分型、重型３组比较各组间的血浆ｔ－ＰＡ、ＰＡＩ－１水平差异及其和预后的关系。结果 脑梗死组、再梗死组的血浆ｔ－ＰＡ、ＰＡＩ－     

Endothelial cells degrade extracellular matrix proteins produced in vitro

Bovine aortic endothelial cells (BAEC) were grown on extracellular matrices produced by vascular smooth muscle cells or fetal bovine endothelial cells. The glycoprotein components of these complex substrates were degraded through activation of the serum zymogen plasminogen to plasmin, as well as by a plasminogen independent protease(s). The plasminogen independent enzyme might be a protease with elastolytic activity since the BAEC digested elastin present in smooth muscle cell derived matrices. The cells also displayed collagenolytic activity on both types of matrices. The addition of the tumor promoter 12-0-tetradecanoyl-phorbol-13-acetate (TPA) (10(-7) M) to the culture medium enhanced considerably the plasminogen activator and collagenolytic activities elaborated by BAEC resulting in an increased degradation rate of matrix glycoprotein and collagen components, whereas the elastolytic activity remained unaffected. Dexamethasone (10(-7) M), although suppressing plasminogen activator (PA) production by BAEC, did not alter their elastolytic activity allowing the cells to degrade the glycoprotein components of the matrices at an unchanged rate. The collagenolytic activity of the BAEC remained unaffected by dexamethasone. These studies demonstrate that BAEC elaborate different proteolytic enzyme activities allowing them to degrade various components of extracellular matrices. These enzymatic activities may be modulated by certain agents thus changing the degradative capabilities of the BAEC.     

Analysis of intrinsic fibrinolysis in human plasma induced by dextran sulfate.

The analysis of normal human plasma by fibrin autography revealed four species of plasminogen activator (PA) activity related to tissue-type PA, factor XII, prekallikrein and urokinase-type PA (u-PA). The u-PA activity increased significantly by incubating plasma with dextran sulfate. This increase was coincident with both the cleavage of factor XII and the complex formation of activated factor XII with its plasma inhibitors, which were determined by immunoblotting procedure. The dextran sulfate-dependent activation of u-PA required both factor XII and prekallikrein, but did not require either plasminogen or factor XI. High molecular weight kininogen was required only at a low concentration of dextran sulfate. Thus the results indicate that the factor XII and prekallikrein-mediated activation of single chain u-PA (scu-PA) operates as a major pathway of scu-PA activation in whole plasma in contact with dextran sulfate.     

Effect of urinary trypsin inhibitor on osteoarthritis

The plasminogen activator (PA) and plasminogen activator inhibitor (PAI) in synovial fluid (SF) of osteoarthritis (OA) were examined to clarify their pathophysiological roles in this disease. Three PAs with molecular weights of 90K, 55K, and 33K were found in the SF, but the 55K PA was dominant. Immunologically, both the 55K and 33K PA were u-PA, while the 90K PA was t-PA. The PAI reacted against both u-PA and t-PA, but the PAI activity against u-PA was much stronger. Urinary trypsin inhibitor (UTI) made a complex with the 55K PA and suppressed the PA activity. A clinical study in which UTI was injected into the joint space of OA (18 joints in 15 patients) revealed excellent (39%), good (16%), and fair (44%) results based on assessment of the pain, range of motion, ballottement and activity of daily living.     

Relationship between smoking and fibrinolytic system with special reference to t-PA and PA inhibitor

Recently tissue plasminogen activator (t-PA) has been clinically applied to the thrombolytic therapy of myocardial infarction. We investigated relationship between cigarette smoking and fibrinolytic system, namely the plasma level of t-PA antigen, plasminogen activator inhibitor (PAI), and PA activity. Nineteen healthy volunteers were asked to smoke for 10 min. The plasma levels of t-PA antigen, PAI activity, PA activity and catecholamine were measured together with measurement of blood pressure and heart rate before, soon after or 30 min after cigarette smoking. Plasma t-PA antigen after cigarette smoking increased to 8.83 +/- 3.11 ng per ml, significantly higher (p less than 0.005) than 6.35 +/- 1.7 ng/ml before cigarette smoking. Plasma PAI activity after cigarette smoking was 5.52 +/- 2.03 u/ml, significantly higher (p less than 0.05) than 4.18 +/- 1.06 u/ml before smoking. Plasma PA activity after smoking was 6.28 +/- 3.85 u/ml significantly higher (p less than 0.05) than 4. 49 +/- 2.74 u/ml. Furthermore, plasma epinephrine level after smoking increased to 59.1 +/- 52.4 pg/ml (p less than 0.1), compared with 36.2 +/- 22.5 pg/ml before smoking. There was a positive correlation between the rate of increase in plasma t-PA antigen and the rate of increase in plasma epinephrine after smoking. It is suggested that plasma epinephrine was related to the mechanism of increased plasma levels of t-PA in cigarette smoking.     

The rabbit as a model for studies of fibrinolysis

When compared to man, the rabbit shows marked prolongation of the dilute whole blood clot lysis time and an attenuated increase in plasminogen activator (PA) after the infusion of desmopressin (DDAVP). The levels of specific components of the plasma fibrinolytic system of the rabbit were compared to those in human plasma to ascertain their role in the differences between species. PA activity and plasminogen levels were similar in the two species. Anti-plasmin and plasminogen activator inhibitor (PAI) activity were lower in the rabbit than in man. The rabbit PAI, apparently similar to that described in man, was not increased by DDAVP infusion. The disparity between man and rabbit with respect to the lysis times of dilute blood clots and response to DDAVP cannot be explained by differences in functional plasma levels of inhibitors or activators of the fibrinolytic system.     

Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells

Endothelial cell migration is stimulated by members of the vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) families, and is dependent on extracellular proteolytic activity provided by enzymes of the plasminogen activator (PA) system. Here we report that in bovine microvascular endothelial cells (BME cells), bFGF principally increased urokinase-type PA (u-PA) while tissue-type PA (t-PA) was increased mainly by VEGF. In bovine aortic endothelial cells (BAE cells), bFGF increased u-PA, whereas VEGF had no effect. Co-added bFGF and VEGF increased t-PA mRNA levels and enzyme activity in both cell types in a synergistic manner. Tissue-type plasminogen activator (t-PA) immunoreactivity colocalized with von Willebrand factor, a marker for Weibel-Palade bodies. Co-added bFGF and VEGF increased the number of t-PA-positive cells as well as the number of t-PA-positive granules per cell. Localization of t-PA in regulated storage granules endows endothelial cells with the potential to rapidly increase proteolytic activity in the pericellular environment.     

Serum factors responsible for unusual induction of plasminogen activator activity in tuberous sclerosis.

Peripheral blood lymphocytes derived from tuberous sclerosis (TS) patients showed unusually high levels of plasminogen activator (PA) activity after treatment with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Serum obtained from peripheral blood of TS patients also enhanced the PA activity level when normal control lymphocytes were incubated with the serum prior to MNNG treatment. Factors exhibiting the enhancing activity were eluted with a solution of about 0.70 M KCl on dye-ligand chromatography, which were inhibited on incubation with an anti-human interferon (HuIFN)-beta antibody, but not with anti-HuIFN-alpha or anti-HuIFN-gamma antibodies. Unlike in the case of HuIFN-beta, the eluted samples did not possess antiviral or anticellular activity. Thus, it seems likely that serum from TS patients contains factors which are responsible for the unusual PA induction and which have a similar epitope to HuIFN-beta.